Drug class: SGLT2 inhibitor Mechanism of Action Empagliflozin inhibits the SGLT2 found in proximal tubules in the kidneys. It reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion (1). It also reduces sodium reabsorption, thereby enhancing tubuloglomerular feedback, lowering intraglomerular pressure, reducing cardiac pre- and afterload, and downregulating sympathetic activity (1). Approved In